Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs Raytheon Technologies Corp (RTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs Raytheon Technologies Corp — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $109.92 (market cap $12.58B), while Raytheon Technologies Corp trades at $184.32 (market cap $248.42B). The key difference: Raytheon Technologies Corp is far larger — about 19.7× Halozyme Therapeutics Inc. Common Stock's market cap, and Raytheon Technologies Corp pays a 1.58% dividend while Halozyme Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 0 Days and Raytheon Technologies Corp for 78 Days on average.
| HALO | RTX | |
|---|---|---|
Market Cap | $12.58B | $248.42B |
Volume | 2,179,278 | 4,380,368 |
Sector | Health | Industrials |
52-Week High | $115.22 | $225.49 |
52-Week Low | $61.63 | $157.00 |
Typical Hold Time | 0 Days | 78 Days |
Enterprise Value | $14.49B | $278.97B |
Dividend Yield | — | 1.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
RTX trades at $180.26, down 1.65% today, amid a bearish technical signal but strong fundamental performance. The company reported three consecutive quarterly earnings beats, with Q3 2026 EPS expected at $1.77. Revenue grew to $88.6B in 2025, with net income margin improving to 7.59%. Analyst consensus remains strongly bullish with a $236.27 price target and 65% buy ratings, supported by a $289B backlog and defense sector tailwinds.
The outlook for RTX is positive given robust defense spending, earnings momentum, and analyst confidence. Risks include execution on large contracts, debt levels, and geopolitical uncertainties. The stock offers growth potential with a 30% upside to consensus target, but investors should monitor quarterly execution and defense budget developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About Raytheon Technologies Corp
Raytheon Technologies is a diversified aerospace and defense industrial company formed from the merger of United Technologies and Raytheon, with roughly equal exposure as a supplier to commercial aerospace manufactures and to the defense market as a prime and subprime contractor.
Read more on RTX →
